Cerebrolysin Research for Stroke
An evidence-based overview of research examining Cerebrolysin in the context of stroke. This page synthesizes findings from peer-reviewed literature.
Research Summary
Cerebrolysin is approved in 50+ countries for stroke treatment. The CARS trial demonstrated significant motor recovery with NNT=5 for clinically meaningful arm improvement. However, the largest trial (CASTA, N=1070) failed its primary endpoint, with benefit only seen in severe stroke subgroups. Cochrane reviews conclude no convincing evidence for mortality or dependence reduction.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Stroke
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cerebrolysin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.